Bristol/Pfizer's Apixaban: Third To Market But Best-In-Class?
This article was originally published in The Pink Sheet Daily
Executive Summary
Top-line results from the Phase III ARISTOTLE trial show the novel anticoagulant was superior to warfarin on safety and efficacy - a pleasant surprise for investors.
You may also be interested in...
Bristol Outperforms In Q3, But Will Dapagliflozin, Apixaban See It Past Plavix?
The big pharma beats analysts' estimates for the third quarter, but all eyes are turned toward its pipeline as the Plavix patent expiry becomes a near-term reality.
Bristol Outperforms In Q3, But Will Dapagliflozin, Apixaban See It Past Plavix?
The big pharma beats analysts' estimates for the third quarter, but all eyes are turned toward its pipeline as the Plavix patent expiry becomes a near-term reality.
Apixaban Shows Mortality Advantage, But Will It Survive FDA Scrutiny?
Bristol-Myers Squibb/Pfizer’s Eliquis (apixaban) may be the first of the new anticoagulants to show a significant mortality benefit in the atrial fibrillation population, but it remains to be seen whether this advantage will withstand FDA’s regulatory scrutiny.